About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

African Americans more likely to develop keloid after head and neck surgery

Source: http://www.news-medical.net/ Author: staff African Americans are seven times more likely than Caucasians to develop an excessive growth of thick, irregularly shaped and raised scarring on their skin - known as a keloid - following head and neck surgery, according to a new study from Henry Ford Hospital in Detroit. This finding, however, is much lower than that previously reported in medical literature, where rates of keloid development have been shown to be up to 16 percent in African Americans. Unlike regular scars, keloids do not subside over time and often extend outside the wound site. Keloids also may be painful to the touch and itchy. "Many African American patients are afraid to have head and neck surgery or any facial cosmetic procedures for fear of developing keloids at the incision sites," says Lamont R. Jones, M.D. vice chair, Department of Otolaryngology-Head and Neck Surgery at Henry Ford. "We hope our study helps to eliminate that fear by showing that keloid development on the head and neck following surgery is actually much smaller than other reports." Much of the uncertainty surrounding keloids is rooted in there being no known cause for their development. But Dr. Jones and his research team at Henry Ford hope to eliminate that unknown. They are embarking on another keloid study to find a new technique to identify the genes that may be responsible for keloid development. By identifying the genetic cause, it may be possible to develop better treatments for keloids in the near future. [...]

2012-03-07T15:24:01-07:00March, 2012|Oral Cancer News|
Read More

Canadian provinces weighing HPV vaccination of boys

Source: www.cmaj.ca/ Author: Laura Eggertson Provinces weighing the merits of implementing the National Advisory Committee on Immunization's recommendation to offer human papillomavirus (HPV) vaccine to boys and men aged 9–26 are facing a tricky trade-off between benefits and costs. “I think the benefits are there, but the costs are high,” which is a crucial issue for publicly funded programs, says Dr. Monika Naus, medical director of immunization programs and vaccine-preventable diseases for the British Columbia Centre for Disease Control. The National Advisory Committee on Immunization last month recommended extending the human papillomavirus vaccine to boys and men aged 9 to 26 “for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2, and 3, anal cancer, and anogenital warts”. The move followed on the heels of an October 2011 recommendation from United States Centers for Disease Control and Prevention advisory panel recommendation that HPV vaccine be given to boys aged 11–12 to ward off genital warts, anal cancer and “possibly” head and neck cancer. In deciding whether to proceed, the provinces should note that “the public health and economic burden of AGWs [anogenital warts] in Canada is considerable, particularly among men whose incidence rates and incidence rate ratios compared to females have been increasing in recent years,” the committee stated. The committee’s report also noted that the number of annual cases (and average annual incidence per 100 000) of penile cancer among men in Canada is 127.4 (1.0 per 100 000), while the number for cancer of the anus is [...]

2012-02-26T10:01:29-07:00February, 2012|Oral Cancer News|
Read More

CD4 counts predict chemo response in laryngeal cancer

Source: www.oncologyreport.com/ Author: Miriam E. Tucker Pretreatment CD4 levels predicted response to induction chemotherapy among 97 patients with advanced laryngeal cancer, but not for 66 patients with advanced oropharyngeal cancer, according to a retrospective analysis of data from two clinical trials. The two groups of head and neck cancer patients were enrolled in two identical prospective, phase II trials of induction chemotherapy and organ preservation, in which tumor response after one cycle of cisplatin and 5-fluorouracil was used to select those who would undergo surgery or definitive chemoradiation (J. Clin. Oncol. 2006;24:593-8 in laryngeal cancer; J. Clin. Oncol. 2008;26:3138-46 in oropharyngeal cancer). Several lymphocyte subsets were measured before treatment via routine flow cytometry in peripheral blood in the laryngeal cancer patients, but only CD4 (helper cell) levels were significantly associated with chemotherapy response. Both absolute CD4 counts and CD4 percentages were higher among induction chemotherapy responders than nonresponders (P = .006 and P = .04, respectively). Investigators also saw a trend for responders to have an increased percentage of CD3 cells (P = .13), decreased percentage of CD8 cells (P = .11), and higher CD4/CD8 ratios. "Host immune parameters are important factors in treatment outcome, and may be useful in identifying subsets of patients with cancers that are responsive to organ-preserving therapy," said Dr. Gregory T. Wolf, who presented the data at a head and neck cancer symposium sponsored by the American Society for Radiation Oncology. "It is likely that immunobiology of head and neck cancers differ significantly by tumor [...]

2012-02-26T09:53:59-07:00February, 2012|Oral Cancer News|
Read More

Radiotherapy technique significantly reduces irradiation of healthy tissue

Source: www.sciencecodex.com/ Author: staff Researchers at the University of Granada and the university hospital Virgen de las Nieves in Granada have developed a new radiotherapy technique that is much less toxic than that traditionally used and only targets cancerous tissue. This new protocol provides a less invasive but equally efficient cancer postoperative treatment for cases of cancer of the oral cavity and pharynx. The study -conducted between 2005 and 2008- included 80 patients diagnosed with epidermoid cancer of the oral cavity and pharynx, who had undergone lymph node removal. The affected nodes were located by the surgeon during the intervention and classified into different risk levels. Classification allowed physicians to target the areas at a higher risk of recurrence. This way, neck areas at a lower risk of containing residual cancer cells were not irradiated. Researchers achieved both to minimize the side effects of radiotherapy, and to reduce treatment discontinuation, thus achieving the therapy to be more effective. A Highly Toxic Treatment Over 70% of oral and pharynx cancer treated with surgery require supplementary treatment with radiotherapy occasionally associated to chemotherapy, because of the high risk for recurrence and spread through the lymph nodes. Radiotherapy and chemotherapy are highly toxic, mainly due to the ulceration of the mucous membranes lining the oral cavity; toxicity leads may patients to stop the treatment, which significantly reduces the chances of cure. By using the risk map obtained with the collaboration of the surgeon and the pathologist, an individualized treatment was designed and adapted [...]

2012-02-26T09:44:04-07:00February, 2012|Oral Cancer News|
Read More

Cancer patients who smoke report worse pain, symptoms

Source: www.medscape.com/ Author: Kate Johnson Cancer patients who smoke experience more severe symptoms than nonsmoking cancer patients and are also at greater risk of misusing opioids, a new study shows. "Our findings show a profile of higher levels of physical symptoms (pain, fatigue, poor appetite, and insomnia) and psychological symptoms (depression and anxiety) among smokers than non-smokers," report Diane Novy, PhD, from the Pain Management Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, and colleagues. The findings underscore the importance of smoking cessation for this patient population, she told Medscape Medical News, even though it's unclear if there is a causal effect. "We don't know the cause. They may smoke more because of the pain," she said in an interview. However, studies also show that smoking has been known to increase certain types of pain such as back pain, and nerve pain, she added. "If we can motivate them to stop smoking, I think they're better off." The findings were presented here at the American Academy of Pain Medicine (AAPM) 28th Annual Meeting. Pain, Fatigue, Insomnia The study included 486 cancer patients (52% female), with a mean age of 55 years, who were referred to the Pain Management Center for uncontrolled pain. Ninety-four patients were smokers, and the rest (n = 356), classified as nonsmokers, were former smokers or never-smokers. The patients were diagnosed with a wide range of cancers, the most common being gastrointestinal (18.5%), followed by hematologic (15%) and head and neck cancer [...]

2012-02-26T09:23:53-07:00February, 2012|Oral Cancer News|
Read More

Post-transplant head and neck tumors tallied

Source: www.familypracticenews.com Author: Damian McNamara, Family Practice News Digital Network Patients who have undergone solid organ transplantation are at greater risk for subsequent tumor development, and head and neck cancers can be particularly aggressive, according to results of a single-institution study. Dr. Robert H. Deeb and his associates at Henry Ford Hospital in Detroit studied 3,639 patients who underwent solid organ transplantation between January 1990 and December 2011. By retrospectively searching electronic medical records, they identified 95 people who developed cutaneous, salivary gland, or mucosal malignancies. They found a 2.1% incidence of cutaneous cancers and a 0.5% incidence of noncutaneous head and neck cancers in this population. Despite a relatively low overall 2.6% incidence, there are reasons for concern, Dr. Deeb said at the Triological Society’s Combined Sections Meeting, which was jointly sponsored by the Triological Society and the American College of Surgeons. When cutaneous cancers did occur, they were more aggressive and were associated with shorter 1-year survival rates. Henry Ford Transplant Institute maintains a noncutaneous tumor registry. This allowed the researchers to compare survival and other factors. Compared with the "nontransplant tumor registry in our institution, we found significantly fewer patients were alive at 1 year," Dr. Deeb said. Specifically, 55% of posttransplant patients with these cancers survived to 1 year, compared with 81% of nontransplant patients. There were no significant differences between groups in terms of age, sex, stage at diagnosis, or 5-year survival. More than half (52%) of the patients who developed skin cancers had multiple [...]

2012-02-19T11:10:20-07:00February, 2012|Oral Cancer News|
Read More

To see or not to see

Source: http://www.rdhmag.com/ Author: JoAnn R. Gurenlian From the National Journal fro Dental Hygiene Professionals: Allow me to relay the experience of a patient who has been through trying times lately. The patient is a middle-age female who noticed a small, firm swelling in the right submandibular region. She had never experienced this type of problem before, but since she had an upcoming visit with her family physician, she thought she would mention it. Her family provider told her it appeared to be a swollen lymph node and recommended she schedule an appointment with her dentist in the event that she had an oral infection. Being conscientious about health issues, this patient did have an examination with her dentist. He advised her that it was a swollen lymph node, but that there were no apparent oral health infections. He reviewed causes of swollen lymph nodes and felt that since she was asymptomatic; the node simply represented residual effects from a cold or allergy condition. Over the course of the next year, this patient presented on several occasions to both her family physician and dentist with concerns that the lymph node was getting larger. Both health care providers told her to “forget about it,” or “it was nothing.” She felt uncertain about both individuals at this point, but since they seemed to be in agreement that her condition “was nothing,” she heeded their advice. After several more months and with ever growing concern, the patient presented to her dentist again for further [...]

2012-02-19T11:00:56-07:00February, 2012|Oral Cancer News|
Read More

Berry Nutrition

Source: www.foodproductdesign.com Author: Marie Spano, M.S., R.D., Contributing Editor Nutritionally speaking, good things come in sweet—and tart—little packages. Research is discovering berries pack a nutritional punch due to their vitamin, fiber and antioxidant content. Botanically speaking, berries are indehiscent fruits (they don’t need to be opened to release their seeds) that ripen through the ovary wall. However, any small, edible fruit with multiple seeds is typically considered a berry. In addition to lending flavor and brilliant colors to a wide variety of dishes, all berries are packed with an array of antioxidants, nutrients and potential health benefits. Berries that are especially antioxidant-rich include fresh crowberries, bilberries, black currants, wild strawberries, blackberries, blueberries, goji berries, sea buckthorn, blueberries and cranberries. However, the antioxidant content of berries varies based on the geographical growing condition. And, while fresh berries are an excellent source of antioxidants, total phenol content drops during processing. In fact, processed berry jams and syrup contain approximately half the antioxidant capacity of fresh berries, and juices show the greatest loss of anthocyanins and tannins due to the removal of seeds and skin (Nutrition Journal, 2010; 9:3; Journal of Agricultural and Food Chemistry, Jan 13, 2012). Botanical berries Shiny, scarlet-colored cranberries are rich in vitamin C, loaded with antioxidants, including flavonoids, and score higher in their ORAC score than many other fruits ("Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods—2007", USDA ARS). Cranberries are perhaps best known for the role their juice plays in the prevention of urinary tract infections (UTI) [...]

2012-02-19T10:53:06-07:00February, 2012|Oral Cancer News|
Read More

Use of carbon nanoparticles paves way to customized cancer therapy

Source: www.azonano.com Author: Cameron Chai A research study by Jeffrey Myers from the University of Texas MD Anderson Cancer Center and James Tour from the Rice University has reported that a combination of carbon nanoparticles and existing drugs has the capability to improve head-and-neck cancer treatment, particularly when coupled with radiation therapy.   The novel technique encapsulates chemotherapeutic drugs using carbon nanoparticles, which sequester the drugs until their delivery into the targeted cancer cells, opening the door to develop customized therapies based on the requirements of individual patients. The researchers have developed a simple technique to mix Cetuximab, a targeting agent, and paclitaxel, a hydrophobic active chemotherapy agent marketed as Taxol, with hydrophilic carbon clusters that are functionalized with polyethylene glycol or PEG-HCC. According to the researchers, Cetuximab, paclitaxel and PEG-HCC ingredients combine easily and form a water-soluble compound that targets tumors more effectively than Taxol, while eliminating the toxic effects of Cremophor EL and paclitaxel on neighboring healthy cells. Cremophor EL is a carrier based on castor oil that makes the hydrophobic paclitaxel into a water-soluble compound and delivers it to patients intravenously. Tour commented that the novel technique utilizes a very small quantity of chemotherapy drug. Myers informed that tests involving the use of Cetuximab, paclitaxel and PEG-HCC ingredients and radiation therapy on mice demonstrated a substantial increase in destroying tumors. The researchers’ hypothesis is paclitaxel detects the tumor cells to the radiation effects and Cetuximab and PEG-HCC augment the delivery of paclitaxel into the cancer cells, Myers [...]

2012-02-19T10:42:23-07:00February, 2012|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top